These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 31351252)
1. Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels. Hubka KM; Carson DD; Harrington DA; Farach-Carson MC Acta Biomater; 2019 Oct; 97():385-398. PubMed ID: 31351252 [TBL] [Abstract][Full Text] [Related]
2. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Farach-Carson MC; Warren CR; Harrington DA; Carson DD Matrix Biol; 2014 Feb; 34():64-79. PubMed ID: 24001398 [TBL] [Abstract][Full Text] [Related]
3. Injectable perlecan domain 1-hyaluronan microgels potentiate the cartilage repair effect of BMP2 in a murine model of early osteoarthritis. Srinivasan PP; McCoy SY; Jha AK; Yang W; Jia X; Farach-Carson MC; Kirn-Safran CB Biomed Mater; 2012 Apr; 7(2):024109. PubMed ID: 22455987 [TBL] [Abstract][Full Text] [Related]
4. Perlecan, A Multi-Functional, Cell-Instructive, Matrix-Stabilizing Proteoglycan With Roles in Tissue Development Has Relevance to Connective Tissue Repair and Regeneration. Hayes AJ; Farrugia BL; Biose IJ; Bix GJ; Melrose J Front Cell Dev Biol; 2022; 10():856261. PubMed ID: 35433700 [TBL] [Abstract][Full Text] [Related]
5. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Cai S; Liu Y; Zheng Shu X; Prestwich GD Biomaterials; 2005 Oct; 26(30):6054-67. PubMed ID: 15958243 [TBL] [Abstract][Full Text] [Related]
6. Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Savorè C; Zhang C; Muir C; Liu R; Wyrwa J; Shu J; Zhau HE; Chung LW; Carson DD; Farach-Carson MC Clin Exp Metastasis; 2005; 22(5):377-90. PubMed ID: 16283481 [TBL] [Abstract][Full Text] [Related]
7. A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation. Farach-Carson MC; Brown AJ; Lynam M; Safran JB; Carson DD Matrix Biol; 2008 Mar; 27(2):150-60. PubMed ID: 17997086 [TBL] [Abstract][Full Text] [Related]
8. SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models. Brasil da Costa FH; Lewis MS; Truong A; Carson DD; Farach-Carson MC PLoS One; 2020; 15(5):e0230354. PubMed ID: 32413029 [TBL] [Abstract][Full Text] [Related]
10. HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses. D'Souza S; Yang W; Marchetti D; Muir C; Farach-Carson MC; Carson DD J Cell Biochem; 2008 Dec; 105(5):1183-93. PubMed ID: 18980226 [TBL] [Abstract][Full Text] [Related]
11. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Castillo GM; Cummings JA; Yang W; Judge ME; Sheardown MJ; Rimvall K; Hansen JB; Snow AD Diabetes; 1998 Apr; 47(4):612-20. PubMed ID: 9568695 [TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury. Gotha L; Lim SY; Osherov AB; Wolff R; Qiang B; Erlich I; Nili N; Pillarisetti S; Chang YT; Tran PK; Tryggvason K; Hedin U; Tran-Lundmark K; Advani SL; Gilbert RE; Strauss BH Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H337-45. PubMed ID: 24858854 [TBL] [Abstract][Full Text] [Related]
13. Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding. Casper CL; Yang W; Farach-Carson MC; Rabolt JF Biomacromolecules; 2007 Apr; 8(4):1116-23. PubMed ID: 17326680 [TBL] [Abstract][Full Text] [Related]
14. Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells. Grindel BJ; Martinez JR; Tellman TV; Harrington DA; Zafar H; Nakhleh L; Chung LW; Farach-Carson MC Sci Rep; 2018 May; 8(1):7262. PubMed ID: 29740048 [TBL] [Abstract][Full Text] [Related]
15. Elevated hypertrophy, growth plate maturation, glycosaminoglycan deposition, and exostosis formation in the Shu CC; Smith SM; Little CB; Melrose J Biochem J; 2019 Jan; 476(2):225-243. PubMed ID: 30563944 [TBL] [Abstract][Full Text] [Related]
16. Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Yang WD; Gomes RR; Alicknavitch M; Farach-Carson MC; Carson DD Tissue Eng; 2005; 11(1-2):76-89. PubMed ID: 15738663 [TBL] [Abstract][Full Text] [Related]
17. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. DeLong SA; Moon JJ; West JL Biomaterials; 2005 Jun; 26(16):3227-34. PubMed ID: 15603817 [TBL] [Abstract][Full Text] [Related]
18. Syndecan-3 and perlecan are differentially expressed by progenitors and mature oligodendrocytes and accumulate in the extracellular matrix. Winkler S; Stahl RC; Carey DJ; Bansal R J Neurosci Res; 2002 Aug; 69(4):477-87. PubMed ID: 12210841 [TBL] [Abstract][Full Text] [Related]
19. The in vitro effects of macrophages on the osteogenic capabilities of MC3T3-E1 cells encapsulated in a biomimetic poly(ethylene glycol) hydrogel. Saleh LS; Carles-Carner M; Bryant SJ Acta Biomater; 2018 Apr; 71():37-48. PubMed ID: 29505890 [TBL] [Abstract][Full Text] [Related]